Physician profile
Harry Giles Cross
NPI 1184690885
$8,084.71
in general payments reported to CMS, 2019-2025
31 companies · $1,635 in 2025
The $1,635 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,693 · 2022: $1,631 · 2023: $1,768 · 2024: $1,358 · 2025: $1,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,761.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $1,299.15 | 2021-2025 | Prolate, Nalocet, Tanlor |
| Collegium Pharmaceutical, INC. | $1,254.32 | 2021-2025 | Xtampza, Belbuca |
| Valinor Pharma, LLC | $1,092.20 | 2023-2025 | Movantik |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $999.96 | 2021-2025 | Relistor |
| Abbvie INC. | $512.13 | 2021-2025 | |
| Indivior INC. | $362.18 | 2021-2025 | Sublocade |
| Redhill Biopharma INC. | $294.22 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $253.25 | 2022-2025 | Quviviq, Quviviq |
| Scilex Pharmaceuticals INC. | $253.05 | 2025 | |
| Hikma Pharmaceuticals USA | $199.99 | 2021-2023 | Kloxxado |
| Biohaven Pharmaceutical Holding Company Ltd. | $184.58 | 2022 | |
| Pfizer INC. | $175.75 | 2021-2023 | |
| Virtus Pharmaceuticals LLC | $158.80 | 2023 | Levorphanol Tartrate |
| Teva Pharmaceuticals USA, INC. | $137.33 | 2021-2023 | Ajovy |
| Lilly USA, LLC | $132.93 | 2021-2023 | Reyvow, Emgality |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $122.13 | 2024-2025 | Brixadi |
| Vertex Pharmaceuticals Incorporated | $117.10 | 2025 | |
| Arbor Pharmaceuticals, INC. | $71.63 | 2021-2022 | |
| Almatica Pharma LLC | $62.05 | 2021 | |
| Grt US Holding, INC. | $57.06 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $51.81 | 2024 | Horizant |
| Biohaven Pharmaceuticals, INC. | $49.76 | 2021 | |
| Novo Nordisk INC | $42.77 | 2022-2023 | Wegovy |
| Horizon Therapeutics Plc | $36.67 | 2021 | |
| Si-Bone, INC. | $28.44 | 2023 | |
| Novartis Pharmaceuticals Corporation | $27.90 | 2021 | |
| Medtronic, INC. | $27.72 | 2025 | Inceptiv |
| Averitas Pharma INC. | $26.46 | 2024 | Qutenza |
| Ibsa Pharma INC. | $20.11 | 2024 | Flector, Licart, Tirosint |
| Alkermes, INC. | $17.45 | 2025 | Vivitrol |
| Takeda Pharmaceuticals U.S.A., INC. | $15.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Cross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.